Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
1.
Infection ; 48(6): 861-870, 2020 Dec.
Artículo en Inglés | MEDLINE | ID: covidwho-680116

RESUMEN

PURPOSE: The coronavirus disease 2019 (COVID-19) outbreak has become a global public health concern; however, relatively few detailed reports of related cardiac injury are available. The aims of this study were to compare the clinical and echocardiographic characteristics of inpatients in the intensive-care unit (ICU) and non-ICU patients. METHODS: We recruited 416 patients diagnosed with COVID-19 and divided them into two groups: ICU (n = 35) and non-ICU (n = 381). Medical histories, laboratory findings, and echocardiography data were compared. RESULTS: The levels of myocardial injury markers in ICU vs non-ICU patients were as follows: troponin I (0.029 ng/mL [0.007-0.063] vs 0.006 ng/mL [0.006-0.006]) and myoglobin (65.45 µg/L [39.77-130.57] vs 37.00 µg/L [26.40-53.54]). Echocardiographic findings included ventricular wall thickening (12 [39%] vs 1 [4%]), pulmonary hypertension (9 [29%] vs 0 [0%]), and reduced left-ventricular ejection fraction (5 [16%] vs 0 [0%]). Overall, 10% of the ICU patients presented with right heart enlargement, thickened right-ventricular wall, decreased right heart function, and pericardial effusion. Cardiac complications were more common in ICU patients, including acute cardiac injury (21 [60%] vs 13 [3%]) (including 2 cases of fulminant myocarditis), atrial or ventricular tachyarrhythmia (3 [9%] vs 3 [1%]), and acute heart failure (5 [14%] vs 0 [0%]). CONCLUSION: Myocardial injury marker elevation, ventricular wall thickening, pulmonary artery hypertension, and cardiac complications including acute myocardial injury, arrhythmia, and acute heart failure are more common in ICU patients with COVID-19. Cardiac injury in COVID-19 patients may be related more to the systemic response after infection rather than direct damage by coronavirus.


Asunto(s)
COVID-19/complicaciones , COVID-19/epidemiología , Cardiopatías/epidemiología , Cardiopatías/etiología , SARS-CoV-2 , Anciano , COVID-19/diagnóstico , COVID-19/virología , China/epidemiología , Comorbilidad , Cuidados Críticos , Ecocardiografía , Femenino , Cardiopatías/diagnóstico , Cardiopatías/mortalidad , Pruebas de Función Cardíaca , Humanos , Masculino , Persona de Mediana Edad , Miocarditis/diagnóstico , Miocarditis/epidemiología , Miocarditis/etiología , Pronóstico , Radiografía Torácica , Evaluación de Síntomas
2.
Infection ; 48(5): 773-777, 2020 Oct.
Artículo en Inglés | MEDLINE | ID: covidwho-45828

RESUMEN

BACKGROUND: Coronavirus disease 2019 (COVID-19) has been demonstrated to be the cause of pneumonia. Nevertheless, it has not been reported as the cause of acute myocarditis or fulminant myocarditis. CASE PRESENTATION: A 63-year-old male was admitted with pneumonia and cardiac symptoms. He was genetically confirmed as having COVID-19 according to sputum testing on the day of admission. He also had elevated troponin I (Trop I) level (up to 11.37 g/L) and diffuse myocardial dyskinesia along with a decreased left ventricular ejection fraction (LVEF) on echocardiography. The highest level of interleukin-6 was 272.40 pg/ml. Bedside chest radiographs showed typical ground-glass changes indicative of viral pneumonia. Laboratory test results for viruses that cause myocarditis were all negative. The patient conformed to the diagnostic criteria of the Chinese expert consensus statement for fulminant myocarditis. After receiving antiviral therapy and mechanical life support, Trop I was reduced to 0.10 g/L, and interleukin-6 was reduced to 7.63 pg/mL. Moreover, the LVEF of the patient gradually recovered to 68%. The patient died of aggravation of secondary infection on the 33rd day of hospitalization. CONCLUSION: COVID-19 patients may develop severe cardiac complications such as myocarditis and heart failure. This is the first report of COVID-19 complicated with fulminant myocarditis. The mechanism of cardiac pathology caused by COVID-19 needs further study.


Asunto(s)
Infecciones por Bacteroides/complicaciones , Betacoronavirus/patogenicidad , Candidiasis/complicaciones , Infecciones por Coronavirus/complicaciones , Miocarditis/complicaciones , Neumonía Viral/complicaciones , Enfermedad Aguda , Antivirales/uso terapéutico , Infecciones por Bacteroides/diagnóstico por imagen , Infecciones por Bacteroides/tratamiento farmacológico , Infecciones por Bacteroides/virología , Betacoronavirus/efectos de los fármacos , Biomarcadores/sangre , COVID-19 , Candidiasis/diagnóstico por imagen , Candidiasis/tratamiento farmacológico , Candidiasis/virología , Infecciones por Coronavirus/diagnóstico por imagen , Infecciones por Coronavirus/tratamiento farmacológico , Infecciones por Coronavirus/virología , Combinación de Medicamentos , Ecocardiografía , Resultado Fatal , Humanos , Interleucina-6/sangre , Lopinavir/uso terapéutico , Masculino , Persona de Mediana Edad , Miocarditis/diagnóstico por imagen , Miocarditis/tratamiento farmacológico , Miocarditis/virología , Pandemias , Combinación Piperacilina y Tazobactam/uso terapéutico , Neumonía Viral/diagnóstico por imagen , Neumonía Viral/tratamiento farmacológico , Neumonía Viral/virología , Ritonavir/uso terapéutico , SARS-CoV-2 , Volumen Sistólico/efectos de los fármacos , Tomografía Computarizada por Rayos X , Troponina I/sangre
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA